Nasdaq · CIK 0001662579
CCCC C4 Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 9 d ago. Close $3.16 on Oct 9, 2026, +85% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
CCCCOct 9, 2026 · close 3.16
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at C4 Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Scott N Boyle Chief Business Officer sell | $3,651 1,159 shares | -1% | - |
Transactions
The last 54 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Donna Roy Grogan director | AGrant or award Common Stock | +4,618 | $3.14 | $15k | 79,471 | 9 d ago |
| Oct 1, 2026 | Kenneth Carl Anderson director | AGrant or award Common Stock | +3,662 | $3.14 | $11k | 75,612 | 9 d ago |
| Sep 18, 2026 | Kendra Adams Chief Financial Officer | MOption exercise Common Stock | +6,250 | $0.00 | $0 | 385,098 | 20 d ago |
| Sep 18, 2026 | Kendra Adams Chief Financial Officer | FTax withholding Common Stock | -2,775 | $3.39 | $9,407 | 382,323 | 20 d ago |
| Jun 18, 2025 | Kenneth Carl Anderson director | AGrant or award Stock Option (Right to Buy)derivative | +35,500 | $0.00 | $0 | 35,500 | Jun 20, 2025 |
| Apr 1, 2025 | Kenneth Carl Anderson director | AGrant or award Common Stock | +7,841 | $1.44 | $11k | 127,609 | Apr 3, 2025 |
| Feb 14, 2025 | Andrew Hirsch President & CEO | AGrant or award Common Stock | +223,500 | $0.00 | $0 | 445,362 | Feb 18, 2025 |
| Feb 13, 2025 | Jolie Siegel Chief Legal Officer | FTax withholding Common Stock | -2,135 | $3.20 | $6,832 | 54,353 | Feb 18, 2025 |
| Feb 13, 2025 | Kelly Schick Chief People Officer | FTax withholding Common Stock | -1,735 | $3.20 | $5,552 | 54,753 | Feb 18, 2025 |
| Feb 13, 2025 | Scott N Boyle Chief Business Officer | FTax withholding Common Stock10b5-1 | -1,735 | $3.20 | $5,552 | 54,832 | Feb 18, 2025 |
| Feb 13, 2025 | Kendra Adams Chief Financial Officer | FTax withholding Common Stock | -1,863 | $3.20 | $5,962 | 82,576 | Feb 18, 2025 |
| Feb 14, 2025 | Mark Mossler Chief Accounting Officer | FTax withholding Common Stock | -1,586 | $3.18 | $5,043 | 18,204 | Feb 18, 2025 |
| Feb 14, 2025 | Paige Mahaney Chief Scientific Officer | AGrant or award Common Stock | +28,200 | $0.00 | $0 | 105,000 | Feb 18, 2025 |
| Feb 14, 2025 | Leonard Reyno Chief Medical Officer | AGrant or award Common Stock | +87,100 | $0.00 | $0 | 178,909 | Feb 18, 2025 |
| Feb 14, 2025 | Leonard Reyno Chief Medical Officer | FTax withholding Common Stock | -5,145 | $3.18 | $16k | 173,764 | Feb 18, 2025 |
| Feb 14, 2025 | Paige Mahaney Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +42,400 | $0.00 | $0 | 42,400 | Feb 18, 2025 |
| Feb 14, 2025 | Kelly Schick Chief People Officer | AGrant or award Common Stock | +56,500 | $0.00 | $0 | 111,253 | Feb 18, 2025 |
| Feb 14, 2025 | Kendra Adams Chief Financial Officer | AGrant or award Common Stock | +87,100 | $0.00 | $0 | 169,676 | Feb 18, 2025 |
| Feb 14, 2025 | Scott N Boyle Chief Business Officer | AGrant or award Common Stock10b5-1 | +56,500 | $0.00 | $0 | 111,332 | Feb 18, 2025 |
| Feb 14, 2025 | Jolie Siegel Chief Legal Officer | AGrant or award Common Stock | +56,500 | $0.00 | $0 | 110,853 | Feb 18, 2025 |
| Feb 14, 2025 | Andrew Hirsch President & CEO | FTax withholding Common Stock | -12,847 | $3.18 | $41k | 432,515 | Feb 18, 2025 |
| Feb 15, 2025 | Andrew Hirsch President & CEO | FTax withholding Common Stock | -9,370 | $3.18 | $30k | 423,145 | Feb 18, 2025 |
| Feb 14, 2025 | Leonard Reyno Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +130,600 | $0.00 | $0 | 130,600 | Feb 18, 2025 |
| Feb 14, 2025 | Scott N Boyle Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -490 | $3.15 | $1,544 | 110,842 | Feb 18, 2025 |
| Feb 14, 2025 | Kelly Schick Chief People Officer | FTax withholding Common Stock | -2,368 | $3.18 | $7,530 | 108,885 | Feb 18, 2025 |
| Feb 14, 2025 | Jolie Siegel Chief Legal Officer | FTax withholding Common Stock | -2,914 | $3.18 | $9,267 | 107,939 | Feb 18, 2025 |
| Feb 14, 2025 | Kendra Adams Chief Financial Officer | FTax withholding Common Stock | -4,559 | $3.18 | $14k | 165,117 | Feb 18, 2025 |
| Feb 14, 2025 | Scott N Boyle Chief Business Officer | FTax withholding Common Stock10b5-1 | -2,368 | $3.18 | $7,530 | 108,474 | Feb 18, 2025 |
| Feb 14, 2025 | Andrew Hirsch President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +335,300 | $0.00 | $0 | 335,300 | Feb 18, 2025 |
| Feb 14, 2025 | Kendra Adams Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +130,600 | $0.00 | $0 | 130,600 | Feb 18, 2025 |
| Feb 14, 2025 | Jolie Siegel Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +84,700 | $0.00 | $0 | 84,700 | Feb 18, 2025 |
| Feb 14, 2025 | Kelly Schick Chief People Officer | AGrant or award Stock Option (Right to Buy)derivative | +84,700 | $0.00 | $0 | 84,700 | Feb 18, 2025 |
| Feb 18, 2025 | Scott N Boyle Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -669 | $3.15 | $2,107 | 107,805 | Feb 18, 2025 |
| Feb 14, 2025 | Scott N Boyle Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +84,700 | $0.00 | $0 | 84,700 | Feb 18, 2025 |
| Jan 2, 2025 | Kenneth Carl Anderson director | AGrant or award Common Stock | +3,074 | $3.66 | $11k | 119,768 | Jan 3, 2025 |
| Jan 2, 2025 | Donna Roy Grogan director | AGrant or award Common Stock | +3,757 | $3.66 | $14k | 32,699 | Jan 3, 2025 |
| Nov 19, 2024 | Steven L. Hoerter director | AGrant or award Stock Option (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Nov 21, 2024 |
| Nov 7, 2024 | Kendra Adams Chief Financial Officer | MOption exercise Common Stock | +3,750 | - | - | 85,541 | Nov 12, 2024 |
| Nov 7, 2024 | Kelly Schick Chief People Officer | MOption exercise Common Stock | +3,750 | - | - | 57,590 | Nov 12, 2024 |
| Nov 7, 2024 | Scott N Boyle Chief Business Officer | MOption exercise Common Stock | +3,750 | - | - | 57,669 | Nov 12, 2024 |
| Nov 7, 2024 | Jolie Siegel Chief Legal Officer | MOption exercise Common Stock | +3,750 | - | - | 57,590 | Nov 12, 2024 |
| Nov 7, 2024 | Andrew Hirsch President & CEO | MOption exercise Common Stock | +12,500 | - | - | 227,412 | Nov 12, 2024 |
| Nov 7, 2024 | Andrew Hirsch President & CEO | FTax withholding Common Stock | -5,550 | $6.04 | $34k | 221,862 | Nov 12, 2024 |
| Nov 7, 2024 | Kelly Schick Chief People Officer | FTax withholding Common Stock | -1,102 | $6.04 | $6,656 | 56,488 | Nov 12, 2024 |
| Nov 7, 2024 | Jolie Siegel Chief Legal Officer | FTax withholding Common Stock | -1,102 | $6.04 | $6,656 | 56,488 | Nov 12, 2024 |
| Nov 7, 2024 | Scott N Boyle Chief Business Officer | FTax withholding Common Stock | -1,102 | $6.04 | $6,656 | 56,567 | Nov 12, 2024 |
| Nov 7, 2024 | Kendra Adams Chief Financial Officer | FTax withholding Common Stock | -1,102 | $6.04 | $6,656 | 84,439 | Nov 12, 2024 |
| Nov 7, 2024 | Andrew Hirsch President & CEO | MOption exercise Performance Restricted Stock Unitsderivative | -12,500 | $0.00 | $0 | 35,000 | Nov 12, 2024 |
| Nov 7, 2024 | Scott N Boyle Chief Business Officer | MOption exercise Performance Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 10,500 | Nov 12, 2024 |
| Nov 7, 2024 | Jolie Siegel Chief Legal Officer | MOption exercise Performance Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 10,500 | Nov 12, 2024 |
| Nov 7, 2024 | Kendra Adams Chief Financial Officer | MOption exercise Performance Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 10,500 | Nov 12, 2024 |
| Nov 7, 2024 | Kelly Schick Chief People Officer | MOption exercise Performance Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 10,500 | Nov 12, 2024 |
| Oct 28, 2024 | Paige Mahaney Chief Scientific Officer | AGrant or award Common Stock | +76,800 | $0.00 | $0 | 76,800 | Oct 29, 2024 |
| Oct 28, 2024 | Paige Mahaney Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +345,600 | $0.00 | $0 | 345,600 | Oct 29, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Kendra AdamsChief Financial Officer
- Kenneth Carl Andersondirector
- Scott N BoyleChief Business Officer
- Donna Roy Grogandirector
- Andrew HirschPresident & CEO
- Steven L. Hoerterdirector
- Paige MahaneyChief Scientific Officer
- Mark MosslerChief Accounting Officer
- Leonard ReynoChief Medical Officer
- Kelly SchickChief People Officer
- Jolie SiegelChief Legal Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.